Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Haijiao, Shen"'
Autor:
Yuankai, Shi, Shiman, Wu, Ke, Wang, Shundong, Cang, Wenxiu, Yao, Yun, Fan, Lin, Wu, Meijuan, Huang, Xingya, Li, Yueyin, Pan, Zhixiong, Yang, Bo, Zhu, Gongyan, Chen, Jianhua, Shi, Meili, Sun, Jian, Fang, Lijun, Wang, Zhaohong, Chen, Chunling, Liu, Jingzhang, Li, Jiwei, Liu, Shenghua, Sun, Yanqiu, Zhao, Yanzhen, Guo, Zili, Meng, Zhefeng, Liu, Zhigang, Han, Hong, Lu, Rui, Ma, Sheng, Hu, Guofang, Zhao, Zheng, Liu, Congying, Xie, Diansheng, Zhong, Hui, Zhao, Huiqing, Yu, Longzhen, Zhang, Minghong, Bi, Shanyong, Yi, Shuliang, Guo, Tienan, Yi, Wen, Li, Yingcheng, Lin, Yongqian, Shu, Zhendong, Chen, Zhongliang, Guo, Michael, Greco, Tingting, Wang, Haijiao, Shen
Publikováno v:
Journal of Thoracic Oncology. 17:1306-1317
Rezivertinib (BPI-7711) is a novel third-generation EGFR tyrosine kinase inhibitor (TKI) targeting both EGFR-sensitizing mutations and EGFR T790M mutation. This study aimed to evaluate the efficacy and safety of rezivertinib in patients with locally
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff897beef424629d3b564488086dc315
https://doi.org/10.1016/j.jtho.2022.08.015
https://doi.org/10.1016/j.jtho.2022.08.015
Autor:
Yuankai Shi, Shiman Wu, Ke Wang, Shundong Cang, Wenxiu Yao, Yun Fan, Lin Wu, Meijuan Huang, Xingya Li, Yueyin Pan, Zhixiong Yang, Bo Zhu, Gongyan Chen, Jianhua Shi, Meili Sun, Jian Fang, Lijun Wang, Zhaohong Chen, Chunling Liu, Jingzhang Li, Jiwei Liu, Shenghua Sun, Yanqiu Zhao, Yanzhen Guo, Zili Meng, Zhefeng Liu, Zhigang Han, Hong Lu, Rui Ma, Shen Hu, Guofang Zhao, Zheng Liu, Congying Xie, Diansheng Zhong, Hui Zhao, Huiqing Yu, Longzhen Zhang, Minghong Bi, Shanyong Yi, Shuliang Guo, Tienan Yi, Wen Li, Yingcheng Lin, Yongqian Shu, Zhendong Chen, Zhongliang Guo, Michael Greco, Tingting Wang, Haijiao Shen
Publikováno v:
SSRN Electronic Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::751976f78fc64167a4a4ede670badcb6
https://doi.org/10.2139/ssrn.4106843
https://doi.org/10.2139/ssrn.4106843
Publikováno v:
International Journal of Multimedia and Ubiquitous Engineering. 10:33-46
Although perceived usefulness and perceived ease of use are two important factors which could directly influence the acceptance of technology and actual usage for digital textbook, less attention has been paid to children’s mobile digital textbook
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0c6200f8c5599561ee7e318a71aca47
https://doi.org/10.14257/ijmue.2015.10.1.4
https://doi.org/10.14257/ijmue.2015.10.1.4
Publikováno v:
Knowledge-Based Systems. 43:103-111
Constraint satisfaction problem has many applications in Artificial Intelligence. Its interactive applications usually require advice from a system to help a user solve the problem. Based on maximal relaxations, the CorrectiveExp algorithm is a repre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1a45c2f77a1ad09604fe9ea25fb3403
https://doi.org/10.1016/j.knosys.2013.01.024
https://doi.org/10.1016/j.knosys.2013.01.024
Publikováno v:
Intelligent Environments
The purpose of this study is to develop an eBooks learning system perceived usefulness and perceived ease of use survey for elementary school students. The sample of this study includes 6672 students (age 6-12) in China who have experience using eBoo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::31c66806e28a5fff00331fe02002f9a2
https://doi.org/10.1109/ie.2014.53
https://doi.org/10.1109/ie.2014.53
Autor:
Yinxiang Wang, Jiang Wan, Junye Wang, K. Ma, Meina Wu, Shunchang Jiao, Li Zhang, Lieming Ding, Jiewen Peng, Aiqin Gu, Changxuan You, Changli Wang, Kejing Ying, Haijiao Shen, Shucai Zhang, Yiping Zhang, Yan Sun, Jintao He, Xueke Jia, Fenlai Tan
Publikováno v:
Journal of Clinical Oncology. 31:e19161-e19161
e19161 Background: The phase III ICOGEN trial established the non-inferiority of icotinib to gefitinib in terms of progression-free survival (PFS), based on which icotinib was approved by State Food and Drug Administration of China. We conducted a sa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d47cc48f8f8cec831edcf0db6410ce4
https://doi.org/10.1200/jco.2013.31.15_suppl.e19161
https://doi.org/10.1200/jco.2013.31.15_suppl.e19161
Publikováno v:
2013 Fourth International Conference on Intelligent Systems Design & Engineering Applications; 2013, p44-47, 4p